Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia

Children's Oncology Group10 enrolled

Overview

RATIONALE: Studying samples of blood or tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in samples from patients with Down syndrome and acute megakaryoblastic leukemia.

OBJECTIVES: * Determine whether megakaryocyte differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor can lead to proliferation arrest, polyploidization, and terminal differentiation of blasts in specimens from patients with Down syndrome and acute megakaryoblastic leukemia. OUTLINE: Cryopreserved specimens are cultured and treated in vivo (in mice) and in vitro with megakaryocytic differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Leukemia

Interventions

cell culture procedureOTHER

laboratory biomarker analysisOTHER

Eligibility

Sex: ALL

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Diagnosis of acute megakaryoblastic leukemia * Diagnosis of Down syndrome * Cryopreserved specimens available PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Outcomes

Primary Outcomes

Proliferation arrest

Polyploidization

Terminal differentiation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.